An interventional study of Alcon 1 piece SA60AT lens and AMO 1-piece AABOO lens in Cataracts, Visual Acuity Reduced Transiently and Loss of Visual Contrast Sensitivity, sponsored by University of Toronto. Terminated at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-08.
Sponsored by University of Toronto · Not applicable, Interventional, and Treatment
The purpose of this study is to seek academic/non-industry research funding support to independently investigate the incidence and density of lens glistenings in cataract patients who are implanted with the latest generations of intraocular lenses (IOL) manufactured by Alcon and AMO Medical Optics.
Glistenings are tiny, clear sparkling, fluid-filled microvacuoles that form within a lens after it has been placed in the eye. Glistenings are seen in all lenses but certain lenses develop a higher number of glistenings than others. The effect of glistenings on patients' visual functioning is largely unknown.
The occurrence of glistenings is in part related to the manufacturing technique. In 2013, manufacturers have claimed that recent improvements in manufacturing process have reduced the occurrence of glistenings. There is a lack of independent evaluation of this claim. We would like to assess independently: 1) How frequently do glistenings occur in patients implanted with the 2015 generation lenses? 2) Is there a difference in glistening occurrence between lenses manufactured by Alcon and Abbott Medical Optics (AMO) - the two largest companies in eye care products?
Two-hundred and seventy-six patients will be randomly assigned to receive Alcon or AMO lenses for their cataract surgery at the Kensington Eye Institute (KEI). After surgery, patients will be instructed to return for follow-up visits at 1 month, 6 months, 12 months and 18 months to assess for the occurrence of glistenings. If glistenings are observed at an earlier follow-up visit (e.g., the 6 month visit), patients will still be instructed to come for future visits so that changes in the glistenings over time can be observed.
Project Time-line:
Months 1-8: Participants recruiting, surgical operations, follow-up visits. Months 9-24: follow-up visits, data entry, cleaning and analysis, early results presentation, manuscript preparation and final report.
Exclusion Criteria:
Alcon 1 piece SA60AT lens
Device: Alcon 1 piece SA60AT lens
AMO 1 piece Sensar AABOO lens
Device: AMO 1-piece AABOO lens
Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-absorbing Acrylate/Methacrylate Copolymer
Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-blocking hydrophobic acrylic
Incidence and density (severity) of glistenings at 18-month follow-up visit
To determine if glistenings develop, eyes are dilated and examined. Photographs of the IOLs will be taken with a slit lamp camera for documentation. These photographs will then be assessed for glistenings in two ways: first by trained ophthalmology staff, and second using the ImageJ software Glistenings will be counted and graded on a scale of 0 to 5+ as following: 0. No glistening 1. Less than 10 glistenings 2. 10 to 25 glistenings 3. 25 to 50 glistenings 4. 50 to 100 glistenings 5. Greater than 100 glistenings
Time frame: 18-month follow-up
Visual acuity in eyes with glistenings at 18-month follow-up visit
Best corrected visual acuity: acuteness/clearness of vision. This will be tested with the ETDRS (early treatment diabetic retinopathy study) chart.
Time frame: 18 month follow-up
Contrast sensitivity in eyes with glistenings at 18-month follow-up visit
Contrast sensitivity: the ability of the visual system to distinguish between an object and its background. This will be tested with the Vector Vision CSV-1000HGT.
Time frame: 18 month follow-up
Glare disability in eyes with glistenings at 18-month follow-up visit
Glare disability: the difficulty seeing in the presence of very bright light such as night-time lighting or sunshine. This will be tested using the Brightness Acuity Tester (BAT).
Time frame: 18 month follow-up
Visual acuity in eyes with glistenings at 12-month follow-up visit
Best corrected visual acuity: acuteness/clearness of vision. This will be tested with the ETDRS (early treatment diabetic retinopathy study) chart
Time frame: 12-month follow-up
Contrast sensitivity and glare disability in eyes with glistenings at 12-month follow-up visit
Contrast sensitivity: the ability of the visual system to distinguish between an object and its background. This will be tested with the Vector Vision CSV-1000HGT.
Time frame: 12-month follow-up
Glare disability in eyes with glistenings at 12-month follow-up visit
Glare disability: the difficulty seeing in the presence of very bright light such as night-time lighting or sunshine. This will be tested using the Brightness Acuity Tester (BAT).
Time frame: 12-month follow-up
Visual acuity in eyes with glistenings at 6-month follow-up visit
Best corrected visual acuity: acuteness/clearness of vision. This will be tested with the ETDRS (early treatment diabetic retinopathy study) chart.
Time frame: 6-month follow-up
Contrast sensitivity in eyes with glistenings at 6-month follow-up visit
Contrast sensitivity: the ability of the visual system to distinguish between an object and its background. This will be tested with the Vector Vision CSV-1000HGT.
Time frame: 6-month follow-up
Glare disability in eyes with glistenings at 6-month follow-up visit
Glare disability: the difficulty seeing in the presence of very bright light such as night-time lighting or sunshine. This will be tested using the Brightness Acuity Tester (BAT).
Time frame: 6-month follow-up
Incidence of glistenings at 12-month follow-up visit
To determine if glistenings develop, eyes are dilated and examined. Photographs of the IOLs will be taken with a slit lamp camera for documentation. These photographs will then be assessed for glistenings in two ways: first by trained ophthalmology staff, and second using the ImageJ software Glistenings will be counted and graded on a scale of 0 to 5+ as following: 0. No glistening 1. Less than 10 glistenings 2. 10 to 25 glistenings 3. 25 to 50 glistenings 4. 50 to 100 glistenings 5. Greater than 100 glistenings
Time frame: 12-month follow-up
Incidence of glistenings at 6-month follow-up visit
To determine if glistenings develop, eyes are dilated and examined. Photographs of the IOLs will be taken with a slit lamp camera for documentation. These photographs will then be assessed for glistenings in two ways: first by trained ophthalmology staff, and second using the ImageJ software Glistenings will be counted and graded on a scale of 0 to 5+ as following: 0. No glistening 1. Less than 10 glistenings 2. 10 to 25 glistenings 3. 25 to 50 glistenings 4. 50 to 100 glistenings 5. Greater than 100 glistenings
Time frame: 6-month follow-up
Plan to share: Undecided
No publications or documents are linked to this record.
This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Toronto